← Latest news 
Wockhardt shares surge 9% as biotech turnaround lifts profit and FY26 growth outlook
Business
Published on 5 May 2026
Turnaround sparked by biotech strength and a revived profit
Wockhardt shares jumped around 9% after the pharma firm reported a strong March-quarter turnaround. Net profit returned to positive territory as revenue rose sharply, and full-year earnings improved too. Biotech operations drove much of the momentum, supported by expansion across emerging markets. The company also said its pipeline grew through new filings and approvals.
- Shares climbed about 9% after a sharp March-quarter turnaround
- Net profit turned positive alongside a major revenue jump
- Biotech expansion in emerging markets supported FY26 growth
- Product pipeline added momentum with new filings and approvals
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times